HIGHBuilt-in & outside partyProduct / Revenue mix
setmelanotide
“10-K Item 1A: 'we have focused substantially all our efforts and financial resources on the research and development of setmelanotide'”
RYTM · Concentration risk · 10-K extracted
Rhythm Pharmaceuticals (RYTM) concentration risks
Updated
The most significant concentration Rhythm Pharmaceuticals discloses is setmelanotide, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Rhythm Pharmaceuticals’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is defined by a single high-share product exposure: the company has focused substantially all of its efforts and financial resources on the research and development of setmelanotide. This is a high-share, mixed-character exposure — partly structural, in that single-asset focus is typical at this stage of rare-disease drug development, and partly dependency in that the company's commercial viability is contingent on the continued regulatory standing, reimbursement dynamics, and clinical adoption of one therapeutic. The mixed character reflects the dual nature of the asset's position: setmelanotide is already approved and generating revenue in the disclosed diseases, making it a commercial asset rather than a pure pipeline candidate, yet the company's growth and cash flow profile are almost entirely dependent on the expansion of its label, market penetration, and protection from competitive entry in its specific ultra-rare indications. A label change, reimbursement restriction, or new competitive approval in these small patient populations could move the investment thesis materially. The filing does not disclose material geographic, customer, or supplier concentrations alongside this product exposure, which is consistent with a small commercial-stage rare disease company whose revenue base is defined by patient numbers and payer coverage in a concentrated disease area rather than by a diversified customer or product portfolio. On balance, the concentration profile is clear and singular: setmelanotide is the company, and performance monitoring reduces to tracking label expansion progress, patient identification rates, and reimbursement sustainability in the relevant jurisdictions.
For the engine’s reasoning on RYTM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| RYTM● | Rhythm Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.